on 20 Jul 2021
Last Applicant/ Owned by
F-75012 Paris
FR
Serial Number
79291480 filed on 24th Jun 2020
Registration Number
6422329 registered on 20th Jul 2021
Filing Basis
No Filing Basis
Disclaimer
NO DATA
Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy The mark consists of the following: the stylized wording "NANOPRIMER" in white against a blue background. Scientific and technological services as well as, namely, research and design services particularly in the field of nanomedicine Read More
Scientific and technological services as well as, namely, research and design services particularly in the field of nanomedicine which is nanotechnology applied to medicine; biological research; research in bacteriology; conducting early evaluations in the field of new pharmaceuticals; design and development of new products for third parties; conducting clinical trials for others in the field of new pharmaceuticals; research services in the field of new pharmaceuticals; chemical analysis; chemical research; chemical engineering; chemical research and analysis services in the field of physico-chemical characterization and concept design; engineering work, namely, surveying; research and development of new products for third parties; technical research in the field of new pharmaceuticals; radiobiology research; research in nanoscience and nanotechnology, especially applied to medicine
Products for medical use especially for metabolic pathways to prevent and treat acid-base imbalance, metabolic brain diseases, disorders of calcium metabolism, DNA repair-deficiency disorders, glucose metabolism disorders, hyperlactatemia, iron metabolism disorders, lipid metabolism disorders, malabsorption syndromes, metabolic syndrome X, inborn error of metabolism, mitochondrial diseases, phosphorus metabolism disorders, porphyrias, proteostasis deficiencies, metabolic skin diseases, wasting syndrome and water-electrolyte imbalance; products for medical use especially for the diagnosis and treatment of tumors; preparations for medical use especially for modifying the bioavailability of therapeutic agents; preparations for medical use especially for modifying liver functions to prevent and treat alcohol-related liver disease, non-alcoholic fatty liver disease, hepatitis, haemochromatosis, primary biliary cirrhosis and liver cancer; preparations for medical use for modifying the functions of the reticuloendothelial system to decrease reticuloendothelial system ability to trap and metabolize therapeutic agents such as nanomedicines, monoclonal antibodies, antibody-drug conjugates, small molecules, and to prevent and treat Gaucher's disease, mastocytosis, and histiocytosis; preparations based on nanomaterials for the delivery of therapeutic agents combined with nucleic acid, small molecules, proteins and peptides; nanoparticles for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, organ transplant rejection; chemical reagents for medical use; bacteriological preparations for medical use; biological preparations for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, organ transplant rejection; enzymes for medical use; enzyme preparations for medical use; diagnostic products for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; drugs for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; medicines for human to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; tonics for medical use to prevent and treat central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; antibiotics; antiseptics; chemico-pharmaceutical preparations for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; pharmaceutical preparations for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection; dietetic substances preparations adapted for medical use; remedies for human medicine for the treatment of central nervous system diseases, cancer, metabolic diseases, infection, immunologic diseases, hematologic disease, rare diseases, and organ transplant rejection
Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy
No 79291480
No Service Mark
No 1780-14786
No
No
No
No
No
No
No
No
The mark consists of the following: the stylized wording "NANOPRIMER" in white against a blue background.
| Status Date | Action Taken |
|---|---|
| 13th Dec 2021 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| 04th Dec 2021 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| 17th Nov 2021 | FINAL DISPOSITION NOTICE SENT TO IB |
| 17th Nov 2021 | FINAL DISPOSITION PROCESSED |
| 20th Oct 2021 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| 20th Jul 2021 | REGISTERED-PRINCIPAL REGISTER |
| 04th May 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 04th May 2021 | PUBLISHED FOR OPPOSITION |
| 02th May 2021 | NOTIFICATION PROCESSED BY IB |
| 14th Apr 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
